Global Multiple Sclerosis (MS) Drugs Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

Report ID: 30446 | Publish Date: May, 2020 | Pages: 156 | Format : PDF

Market Overview

The global Multiple Sclerosis (MS) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Multiple Sclerosis (MS) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation

Multiple Sclerosis (MS) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Multiple Sclerosis (MS) Drugs market has been segmented into

    Copaxone (Glatiramer Acetate, Copolymer 1)

    Novantrone (Mitoxantrone)

    Gilenya (Fingolimod, Fty720)

    Aubagio (Teriflunomide)

    Tecfidera (Dimethyl Fumarate)

    Firategrast (Sb683699, T-0047)

    Siponimod (Baf312)

    Others

By Application, Multiple Sclerosis (MS) Drugs has been segmented into:

    RRMS

    SPMS

    PPMS

    PRMS

Regions and Countries Level Analysis

Regional analysis is another highly comprehensive part of the research and analysis study of the global Multiple Sclerosis (MS) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Multiple Sclerosis (MS) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Multiple Sclerosis (MS) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Multiple Sclerosis (MS) Drugs market in important countries (regions), including:

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Russia and Italy)

    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

    South America (Brazil, Argentina, etc.)

    Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Multiple Sclerosis (MS) Drugs Market Share Analysis

Multiple Sclerosis (MS) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Multiple Sclerosis (MS) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Multiple Sclerosis (MS) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Multiple Sclerosis (MS) Drugs are:

    Bayer AG

    Antisense Therapeutics

    Cinnagen

    Bayhill Therapeutics

    Fast Forward Llc

    Biogen Idec

    Five Prime Therapeutics

    Eli Lilly

    Daiichi Sankyo

    Apitope

    Gw Pharmaceuticals

    Genmab

    Innate Immunotherapeutics

    Glaxosmithkline

    Artielle Immunotherapeutics

    Genzyme

Among other players domestic and global, Multiple Sclerosis (MS) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Multiple Sclerosis (MS) Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Multiple Sclerosis (MS) Drugs, with price, sales, revenue and global market share of Multiple Sclerosis (MS) Drugs in 2018 and 2019.

Chapter 3, the Multiple Sclerosis (MS) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Multiple Sclerosis (MS) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.

Chapter 12, Multiple Sclerosis (MS) Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.

Chapter 13, 14 and 15, to describe Multiple Sclerosis (MS) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.


Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

    1.1 Multiple Sclerosis (MS) Drugs Introduction

    1.2 Market Analysis by Type

        1.2.1 Overview: Global Multiple Sclerosis (MS) Drugs Revenue by Type: 2015 VS 2019 VS 2025

        1.2.2 Copaxone (Glatiramer Acetate, Copolymer 1)

        1.2.3 Novantrone (Mitoxantrone)

        1.2.4 Gilenya (Fingolimod, Fty720)

        1.2.5 Aubagio (Teriflunomide)

        1.2.6 Tecfidera (Dimethyl Fumarate)

        1.2.7 Firategrast (Sb683699, T-0047)

        1.2.8 Siponimod (Baf312)

        1.2.9 Others

    1.3 Market Analysis by Application

        1.3.1 Overview: Global Multiple Sclerosis (MS) Drugs Revenue by Application: 2015 VS 2019 VS 2025

        1.3.2 RRMS

        1.3.3 SPMS

        1.3.4 PPMS

        1.3.5 PRMS

    1.4 Overview of Global Multiple Sclerosis (MS) Drugs Market

        1.4.1 Global Multiple Sclerosis (MS) Drugs Market Status and Outlook (2015-2025)

        1.4.2 North America (United States, Canada and Mexico)

        1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)

        1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

        1.4.5 South America, Middle East & Africa

    1.5 Market Dynamics

        1.5.1 Market Opportunities

        1.5.2 Market Risk

        1.5.3 Market Driving Force

2 Manufacturers Profiles

    2.1 Bayer AG

        2.1.1 Bayer AG Details

        2.1.2 Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis

        2.1.3 Bayer AG SWOT Analysis

        2.1.4 Bayer AG Product and Services

        2.1.5 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.2 Antisense Therapeutics

        2.2.1 Antisense Therapeutics Details

        2.2.2 Antisense Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis

        2.2.3 Antisense Therapeutics SWOT Analysis

        2.2.4 Antisense Therapeutics Product and Services

        2.2.5 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.3 Cinnagen

        2.3.1 Cinnagen Details

        2.3.2 Cinnagen Major Business and Total Revenue (Financial Highlights) Analysis

        2.3.3 Cinnagen SWOT Analysis

        2.3.4 Cinnagen Product and Services

        2.3.5 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.4 Bayhill Therapeutics

        2.4.1 Bayhill Therapeutics Details

        2.4.2 Bayhill Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis

        2.4.3 Bayhill Therapeutics SWOT Analysis

        2.4.4 Bayhill Therapeutics Product and Services

        2.4.5 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.5 Fast Forward Llc

        2.5.1 Fast Forward Llc Details

        2.5.2 Fast Forward Llc Major Business and Total Revenue (Financial Highlights) Analysis

        2.5.3 Fast Forward Llc SWOT Analysis

        2.5.4 Fast Forward Llc Product and Services

        2.5.5 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.6 Biogen Idec

        2.6.1 Biogen Idec Details

        2.6.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis

        2.6.3 Biogen Idec SWOT Analysis

        2.6.4 Biogen Idec Product and Services

        2.6.5 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.7 Five Prime Therapeutics

        2.7.1 Five Prime Therapeutics Details

        2.7.2 Five Prime Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis

        2.7.3 Five Prime Therapeutics SWOT Analysis

        2.7.4 Five Prime Therapeutics Product and Services

        2.7.5 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.8 Eli Lilly

        2.8.1 Eli Lilly Details

        2.8.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis

        2.8.3 Eli Lilly SWOT Analysis

        2.8.4 Eli Lilly Product and Services

        2.8.5 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.9 Daiichi Sankyo

        2.9.1 Daiichi Sankyo Details

        2.9.2 Daiichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis

        2.9.3 Daiichi Sankyo SWOT Analysis

        2.9.4 Daiichi Sankyo Product and Services

        2.9.5 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.10 Apitope

        2.10.1 Apitope Details

        2.10.2 Apitope Major Business and Total Revenue (Financial Highlights) Analysis

        2.10.3 Apitope SWOT Analysis

        2.10.4 Apitope Product and Services

        2.10.5 Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.11 Gw Pharmaceuticals

        2.11.1 Gw Pharmaceuticals Details

        2.11.2 Gw Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis

        2.11.3 Gw Pharmaceuticals SWOT Analysis

        2.11.4 Gw Pharmaceuticals Product and Services

        2.11.5 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.12 Genmab

        2.12.1 Genmab Details

        2.12.2 Genmab Major Business and Total Revenue (Financial Highlights) Analysis

        2.12.3 Genmab SWOT Analysis

        2.12.4 Genmab Product and Services

        2.12.5 Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.13 Innate Immunotherapeutics

        2.13.1 Innate Immunotherapeutics Details

        2.13.2 Innate Immunotherapeutics Major Business and Total Revenue (Financial Highlights) Analysis

        2.13.3 Innate Immunotherapeutics SWOT Analysis

        2.13.4 Innate Immunotherapeutics Product and Services

        2.13.5 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.14 Glaxosmithkline

        2.14.1 Glaxosmithkline Details

        2.14.2 Glaxosmithkline Major Business and Total Revenue (Financial Highlights) Analysis

        2.14.3 Glaxosmithkline SWOT Analysis

        2.14.4 Glaxosmithkline Product and Services

        2.14.5 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.15 Artielle Immunotherapeutics

        2.15.1 Artielle Immunotherapeutics Details

        2.15.2 Artielle Immunotherapeutics Major Business and Total Revenue (Financial Highlights) Analysis

        2.15.3 Artielle Immunotherapeutics SWOT Analysis

        2.15.4 Artielle Immunotherapeutics Product and Services

        2.15.5 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    2.16 Genzyme

        2.16.1 Genzyme Details

        2.16.2 Genzyme Major Business and Total Revenue (Financial Highlights) Analysis

        2.16.3 Genzyme SWOT Analysis

        2.16.4 Genzyme Product and Services

        2.16.5 Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

3 Sales, Revenue and Market Share by Manufacturer

    3.1 Global Multiple Sclerosis (MS) Drugs Sales and Market Share by Manufacturer (2018-2019)

    3.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Manufacturer (2018-2019)

    3.3 Market Concentration Rate

        3.3.1 Top 3 Multiple Sclerosis (MS) Drugs Manufacturer Market Share in 2019

        3.3.2 Top 6 Multiple Sclerosis (MS) Drugs Manufacturer Market Share in 2019

    3.4 Market Competition Trend

4 Global Market Analysis by Regions

    4.1 Global Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Regions

        4.1.1 Global Multiple Sclerosis (MS) Drugs Sales and Market Share by Regions (2015-2020)

        4.1.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Regions (2015-2020)

    4.2 North America Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    4.3 Europe Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    4.4 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    4.5 South America Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    4.6 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

5 North America by Country

    5.1 North America Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Country

        5.1.1 North America Multiple Sclerosis (MS) Drugs Sales and Market Share by Country (2015-2020)

        5.1.2 North America Multiple Sclerosis (MS) Drugs Revenue and Market Share by Country (2015-2020)

    5.2 United States Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    5.3 Canada Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    5.4 Mexico Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

6 Europe by Country

    6.1 Europe Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Country

        6.1.1 Europe Multiple Sclerosis (MS) Drugs Sales and Market Share by Country (2015-2020)

        6.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue and Market Share by Country (2015-2020)

    6.2 Germany Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    6.3 UK Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    6.4 France Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    6.5 Russia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    6.6 Italy Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

7 Asia-Pacific by Regions

    7.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Regions

        7.1.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Market Share by Regions (2015-2020)

        7.1.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Market Share by Regions (2015-2020)

    7.2 China Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    7.3 Japan Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    7.4 Korea Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    7.5 India Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    7.6 Southeast Asia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    7.7 Australia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

8 South America by Country

    8.1 South America Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Country

        8.1.1 South America Multiple Sclerosis (MS) Drugs Sales and Market Share by Country (2015-2020)

        8.1.2 South America Multiple Sclerosis (MS) Drugs Revenue and Market Share by Country (2015-2020)

    8.2 Brazil Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    8.3 Argentina Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

9 Middle East & Africa by Countries

    9.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, Revenue and Market Share by Country

        9.1.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales and Market Share by Country (2015-2020)

        9.1.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue and Market Share by Country (2015-2020)

    9.2 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    9.3 Turkey Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    9.4 Egypt Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    9.5 South Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

10 Market Segment by Type

    10.1 Global Multiple Sclerosis (MS) Drugs Sales and Market Share by Type (2015-2020)

    10.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2015-2020)

    10.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2015-2020)

11 Global Multiple Sclerosis (MS) Drugs Market Segment by Application

    11.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2015-2020)

    11.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2015-2020)

    11.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2015-2020)

12 Market Forecast

    12.1 Global Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate (2021-2025)

    12.2 Multiple Sclerosis (MS) Drugs Market Forecast by Regions (2021-2025)

        12.2.1 North America Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025)

        12.2.2 Europe Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025)

        12.2.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025)

        12.2.4 South America Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025)

        12.2.5 Middle East & Africa Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025)

    12.3 Multiple Sclerosis (MS) Drugs Market Forecast by Type (2021-2025)

        12.3.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2021-2025)

        12.3.2 Global Multiple Sclerosis (MS) Drugs Market Share Forecast by Type (2021-2025)

    12.4 Multiple Sclerosis (MS) Drugs Market Forecast by Application (2021-2025)

        12.4.1 Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2021-2025)

        12.4.2 Global Multiple Sclerosis (MS) Drugs Market Share Forecast by Application (2021-2025)

13 Sales Channel, Distributors, Traders and Dealers

    13.1 Sales Channel

        13.1.1 Direct Marketing

        13.1.2 Indirect Marketing

    13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

    15.1 Methodology

    15.2 Data Source

    15.3 Disclaimer

    15.4 About US

List of Tables

    Table 1. Global Multiple Sclerosis (MS) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025

    Table 2. Breakdown of Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

    Table 3. Global Multiple Sclerosis (MS) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025

    Table 4. Market Opportunities in Next Few Years

    Table 5. Market Risks Analysis

    Table 6. Market Drivers

    Table 7. Bayer AG Basic Information, Manufacturing Base and Competitors

    Table 8. Bayer AG Multiple Sclerosis (MS) Drugs Major Business

    Table 9. Bayer AG Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 10. Bayer AG SWOT Analysis

    Table 11. Bayer AG Multiple Sclerosis (MS) Drugs Product and Services

    Table 12. Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 13. Antisense Therapeutics Basic Information, Manufacturing Base and Competitors

    Table 14. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Major Business

    Table 15. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 16. Antisense Therapeutics SWOT Analysis

    Table 17. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product and Services

    Table 18. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 19. Cinnagen Basic Information, Manufacturing Base and Competitors

    Table 20. Cinnagen Multiple Sclerosis (MS) Drugs Major Business

    Table 21. Cinnagen Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 22. Cinnagen SWOT Analysis

    Table 23. Cinnagen Multiple Sclerosis (MS) Drugs Product and Services

    Table 24. Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 25. Bayhill Therapeutics Basic Information, Manufacturing Base and Competitors

    Table 26. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Major Business

    Table 27. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 28. Bayhill Therapeutics SWOT Analysis

    Table 29. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product and Services

    Table 30. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 31. Fast Forward Llc Basic Information, Manufacturing Base and Competitors

    Table 32. Fast Forward Llc Multiple Sclerosis (MS) Drugs Major Business

    Table 33. Fast Forward Llc Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 34. Fast Forward Llc SWOT Analysis

    Table 35. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product and Services

    Table 36. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 37. Biogen Idec Basic Information, Manufacturing Base and Competitors

    Table 38. Biogen Idec Multiple Sclerosis (MS) Drugs Major Business

    Table 39. Biogen Idec Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 40. Biogen Idec SWOT Analysis

    Table 41. Biogen Idec Multiple Sclerosis (MS) Drugs Product and Services

    Table 42. Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 43. Five Prime Therapeutics Basic Information, Manufacturing Base and Competitors

    Table 44. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Major Business

    Table 45. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 46. Five Prime Therapeutics SWOT Analysis

    Table 47. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product and Services

    Table 48. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 49. Eli Lilly Basic Information, Manufacturing Base and Competitors

    Table 50. Eli Lilly Multiple Sclerosis (MS) Drugs Major Business

    Table 51. Eli Lilly Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 52. Eli Lilly SWOT Analysis

    Table 53. Eli Lilly Multiple Sclerosis (MS) Drugs Product and Services

    Table 54. Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 55. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors

    Table 56. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Major Business

    Table 57. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 58. Daiichi Sankyo SWOT Analysis

    Table 59. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product and Services

    Table 60. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 61. Apitope Basic Information, Manufacturing Base and Competitors

    Table 62. Apitope Multiple Sclerosis (MS) Drugs Major Business

    Table 63. Apitope Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 64. Apitope SWOT Analysis

    Table 65. Apitope Multiple Sclerosis (MS) Drugs Product and Services

    Table 66. Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 67. Gw Pharmaceuticals Basic Information, Manufacturing Base and Competitors

    Table 68. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Major Business

    Table 69. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 70. Gw Pharmaceuticals SWOT Analysis

    Table 71. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product and Services

    Table 72. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 73. Genmab Basic Information, Manufacturing Base and Competitors

    Table 74. Genmab Multiple Sclerosis (MS) Drugs Major Business

    Table 75. Genmab Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 76. Genmab SWOT Analysis

    Table 77. Genmab Multiple Sclerosis (MS) Drugs Product and Services

    Table 78. Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 79. Innate Immunotherapeutics Basic Information, Manufacturing Base and Competitors

    Table 80. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Business

    Table 81. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 82. Innate Immunotherapeutics SWOT Analysis

    Table 83. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product and Services

    Table 84. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 85. Glaxosmithkline Basic Information, Manufacturing Base and Competitors

    Table 86. Glaxosmithkline Multiple Sclerosis (MS) Drugs Major Business

    Table 87. Glaxosmithkline Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 88. Glaxosmithkline SWOT Analysis

    Table 89. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product and Services

    Table 90. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 91. Artielle Immunotherapeutics Basic Information, Manufacturing Base and Competitors

    Table 92. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Business

    Table 93. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 94. Artielle Immunotherapeutics SWOT Analysis

    Table 95. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product and Services

    Table 96. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 97. Genzyme Basic Information, Manufacturing Base and Competitors

    Table 98. Genzyme Multiple Sclerosis (MS) Drugs Major Business

    Table 99. Genzyme Multiple Sclerosis (MS) Drugs Total Revenue (USD Million) (2018-2019)

    Table 100. Genzyme SWOT Analysis

    Table 101. Genzyme Multiple Sclerosis (MS) Drugs Product and Services

    Table 102. Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)

    Table 103. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturer (2018-2019) (K Pcs)

    Table 104. Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturer (2018-2019) (USD Million)

    Table 105. Global Multiple Sclerosis (MS) Drugs Sales by Regions (2015-2020) (K Pcs)

    Table 106. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Regions (2015-2020)

    Table 107. Global Multiple Sclerosis (MS) Drugs Revenue by Regions (2015-2020) (USD Million)

    Table 108. North America Multiple Sclerosis (MS) Drugs Sales by Countries (2015-2020) (K Pcs)

    Table 109. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2015-2020)

    Table 110. North America Multiple Sclerosis (MS) Drugs Revenue by Countries (2015-2020) (USD Million)

    Table 111. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020)

    Table 112. Europe Multiple Sclerosis (MS) Drugs Sales by Countries (2015-2020) (K Pcs)

    Table 113. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2015-2020)

    Table 114. Europe Multiple Sclerosis (MS) Drugs Revenue by Countries (2015-2020) (USD Million)

    Table 115. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Regions (2015-2020) (K Pcs)

    Table 116. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Regions (2015-2020)

    Table 117. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue by Regions (2015-2020) (USD Million)

    Table 118. South America Multiple Sclerosis (MS) Drugs Sales by Countries (2015-2020) (K Pcs)

    Table 119. South America Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2015-2020)

    Table 120. South America Multiple Sclerosis (MS) Drugs Revenue by Countries (2015-2020) (USD Million)

    Table 121. South America Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020)

    Table 122. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Countries (2015-2020) (K Pcs)

    Table 123. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2015-2020)

    Table 124. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Countries (2015-2020) (USD Million)

    Table 125. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020)

    Table 126. Global Multiple Sclerosis (MS) Drugs Sales by Type (2015-2020) (K Pcs)

    Table 127. Global Multiple Sclerosis (MS) Drugs Sales Share by Type (2015-2020)

    Table 128. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2015-2020) (USD Million)

    Table 129. Global Multiple Sclerosis (MS) Drugs Revenue Share by Type (2015-2020)

    Table 130. Global Multiple Sclerosis (MS) Drugs Sales by Application (2015-2020) (K Pcs)

    Table 131. Global Multiple Sclerosis (MS) Drugs Sales Share by Application (2015-2020)

    Table 132. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Regions (2021-2025) (K Pcs)

    Table 133. Global Multiple Sclerosis (MS) Drugs Market Share Forecast by Regions (2021-2025)

    Table 134. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2021-2025) (K Pcs)

    Table 135. Global Multiple Sclerosis (MS) Drugs Market Share Forecast by Type (2021-2025)

    Table 136. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2021-2025)

    Table 137. Global Multiple Sclerosis (MS) Drugs Market Share Forecast by Application (2021-2025)

    Table 138. Direct Channel Pros & Cons

    Table 139. Indirect Channel Pros & Cons

    Table 140. Distributors/Traders/ Dealers List

List of Figures

    Figure 1. Multiple Sclerosis (MS) Drugs Picture

    Figure 2. Global Sales Market Share of Multiple Sclerosis (MS) Drugs by Type in 2019

    Figure 3. Copaxone (Glatiramer Acetate, Copolymer 1) Picture

    Figure 4. Novantrone (Mitoxantrone) Picture

    Figure 5. Gilenya (Fingolimod, Fty720) Picture

    Figure 6. Aubagio (Teriflunomide) Picture

    Figure 7. Tecfidera (Dimethyl Fumarate) Picture

    Figure 8. Firategrast (Sb683699, T-0047) Picture

    Figure 9. Siponimod (Baf312) Picture

    Figure 10. Others Picture

    Figure 11. Multiple Sclerosis (MS) Drugs Sales Market Share by Application in 2018

    Figure 12. RRMS Picture

    Figure 13. SPMS Picture

    Figure 14. PPMS Picture

    Figure 15. PRMS Picture

    Figure 16. Global Multiple Sclerosis (MS) Drugs Market Status and Outlook (2015-2025) (USD Million)

    Figure 17. United States Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 18. Canada Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 19. Mexico Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 20. Germany Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 21. France Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 22. UK Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 23. Russia Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 24. Italy Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 25. China Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 26. Japan Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 27. Korea Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 28. India Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 29. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 30. Australia Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)

    Figure 31. Brazil Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 32. Egypt Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 33. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 34. South Africa Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 35. Turkey Multiple Sclerosis (MS) Drugs Revenue (Value) and Growth Rate (2015-2025)

    Figure 36. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturer in 2019

    Figure 37. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturer in 2019

    Figure 38. Top 3 Multiple Sclerosis (MS) Drugs Manufacturer (Revenue) Market Share in 2019

    Figure 39. Top 6 Multiple Sclerosis (MS) Drugs Manufacturer (Revenue) Market Share in 2019

    Figure 40. Key Manufacturer Market Share Trend

    Figure 41. Global Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 42. Global Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 43. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions (2015-2020)

    Figure 44. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2018

    Figure 45. North America Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    Figure 46. Europe Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    Figure 47. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    Figure 48. South America Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    Figure 49. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020)

    Figure 50. North America Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 51. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Countries (2015-2020)

    Figure 52. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Countries in 2018

    Figure 53. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020) (USD Million)

    Figure 54. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2018

    Figure 55. United States Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 56. Canada Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 57. Mexico Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 58. Europe Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 59. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020)

    Figure 60. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2019

    Figure 61. Germany Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 62. UK Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 63. France Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 64. Russia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 65. Italy Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 66. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 67. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Regions 2019

    Figure 68. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions 2019

    Figure 69. China Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 70. Japan Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 71. Korea Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 72. India Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 73. Southeast Asia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 74. South America Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 75. South America Multiple Sclerosis (MS) Drugs Sales Market Share by Countries in 2019

    Figure 76. South America Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2019

    Figure 77. Brazil Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 78. Argentina Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 79. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2015-2020) (USD Million)

    Figure 80. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Countries in 2019

    Figure 81. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries (2015-2020)

    Figure 82. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Countries in 2019

    Figure 83. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 84. Egypt Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 85. Turkey Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 86. South Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2015-2020) (K Pcs)

    Figure 87. Global Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2025) (K Pcs)

    Figure 88. Global Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2021-2025) (USD Million)

    Figure 89. North America Sales Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025) (K Pcs)

    Figure 90. Europe Sales Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025) (K Pcs)

    Figure 91. Asia-Pacific Sales Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025) (K Pcs)

    Figure 92. South America Sales Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025) (K Pcs)

    Figure 93. Middle East & Africa Sales Multiple Sclerosis (MS) Drugs Market Forecast (2021-2025) (K Pcs)

    Figure 94. Sales Channel: Direct Channel vs Indirect Channel

Our Clients